J
uno Therapeutics is abandoning a cancer therapy that once looked like a revolutionary advance, reacting to a rash of patient deaths that made the customized treatment too risky to push forward.
The company’s decision changes the landscape in a blockbuster race to commercialize the first CAR-T technology, a promising new approach to cancer in which patients’ own immune cells are rewired to attack tumors. Juno, once a leader in the field, is now more than a year behind rivals Kite Pharma and Novartis.
Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
